Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.42 |
| ▸ | PPARG | P37231 | 8/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 3/20 | 0.37 |
| ▸ | PDE6C | P51160 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14184497 | 1.00 | PPARA (0.42) | PPARAPPARGPPARDPDE5APDE6C | |
| SCHEMBL3840054 | 0.93 | PPARA (0.52) | PPARAPPARGPPARDPDE5ATLR7 | |
| SCHEMBL3839913 | 0.92 | PPARA (0.45) | PPARAPPARGPDE5APDE6CTLR7 | |
| SCHEMBL3844928 | 0.91 | PPARA (0.40) | PPARAPPARGPPARDPDE5APDE6C | |
| SCHEMBL14184495 | 0.90 | PDE5A (0.37) | PPARAPPARGPPARDPDE5APDE6C | |
| SCHEMBL14184564 | 0.90 | PPARA (0.38) | PPARAPPARGPPARDPDE5APDE6C | |
| SCHEMBL4918197 | 0.89 | PPARA (0.40) | PPARAPPARGPPARDPDE5APDE6C | |
| SCHEMBL3847412 | 0.89 | PPARA (0.40) | PPARAPPARGPPARDPDE5APDE6C | |
| SCHEMBL3839151 | 0.89 | PPARA (0.40) | PPARAPPARGPPARDPDE5APDE6C | |
| SCHEMBL3839997 | 0.88 | PPARA (0.55) | PPARAPPARGTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1793828-A4 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | REDDYS LAB LTD DR (IN) | 2009-09-02 | — | — | EP | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1793828-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | Dr. Reddy's Laboratories Ltd. (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006029075-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | PPARA, PPARD, PPARG | PPARA 1/4885PPARG 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.